Literature DB >> 8443766

How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer.

G M Clark1, C R Wenger, S Beardslee, M A Owens, G Pounds, T Oldaker, P Vendely, M R Pandian, D Harrington, W L McGuire.   

Abstract

A large group of patients with node-positive breast cancer was divided into a training set (n = 851) and a validation set (n = 432) to demonstrate techniques for integrating steroid hormone receptor status, DNA flow cytometric findings, and other prognostic factors to predict patient survival. Multivariate analyses showed that estrogen receptor status, the number of involved axillary lymph nodes, patient age, S-phase fraction, progesterone receptor status, and tumor size were significant predictors of survival in patients with node-positive breast cancer. Techniques for optimizing and validating a cut point for a new prognostic factor and for examining alternative representations of prognostic factors were demonstrated. Prognostic indexes were created that could be used to identify patients with very good or very poor prognoses.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8443766     DOI: 10.1002/1097-0142(19930315)71:6+<2157::aid-cncr2820711606>3.0.co;2-o

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  Analysis of estrogen receptor messenger RNA in breast carcinomas from archival specimens is predictive of tumor biology.

Authors:  C Carmeci; E C deConinck; T Lawton; D A Bloch; R J Weigel
Journal:  Am J Pathol       Date:  1997-05       Impact factor: 4.307

2.  Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.

Authors:  C I Utech; C S Young; P F Winter
Journal:  Eur J Nucl Med       Date:  1996-12

Review 3.  Prognostic factors: rationale and methods of analysis and integration.

Authors:  G M Clark; S G Hilsenbeck; P M Ravdin; M De Laurentiis; C K Osborne
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

4.  Prognostic role of oestrogen and progesterone receptors in patients with breast cancer: relation to age and lymph node status.

Authors:  K Collett; F Hartveit; R Skjaerven; B O Maehle
Journal:  J Clin Pathol       Date:  1996-11       Impact factor: 3.411

5.  Tamoxifen resistance in early breast cancer: statistical modelling of tissue markers to improve risk prediction.

Authors:  M R Baneshi; P Warner; N Anderson; J Edwards; T G Cooke; J M S Bartlett
Journal:  Br J Cancer       Date:  2010-05-11       Impact factor: 7.640

6.  Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells.

Authors:  Stephanie Harkey Shirley; Joyce E Rundhaug; Jie Tian; Noirin Cullinan-Ammann; Isabel Lambertz; Claudio J Conti; Robin Fuchs-Young
Journal:  Cancer Res       Date:  2009-04-07       Impact factor: 12.701

7.  Transcriptional regulation of estrogen receptor in breast carcinomas.

Authors:  E C deConinck; L A McPherson; R J Weigel
Journal:  Mol Cell Biol       Date:  1995-04       Impact factor: 4.272

8.  Do we really need prognostic factors for breast cancer?

Authors:  G M Clark
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

9.  Intensive post-operative follow-up of breast cancer patients with tumour markers: CEA, TPA or CA15.3 vs MCA and MCA-CA15.3 vs CEA-TPA-CA15.3 panel in the early detection of distant metastases.

Authors:  Andrea Nicolini; Gianna Tartarelli; Angelo Carpi; Maria Rita Metelli; Paola Ferrari; Loretta Anselmi; Massimo Conte; Piero Berti; Paolo Miccoli
Journal:  BMC Cancer       Date:  2006-11-20       Impact factor: 4.430

10.  Flow cytometric analysis of S-phase fraction in breast carcinomas using gating on cells containing cytokeratin. South East Sweden Breast Cancer Group.

Authors:  S Wingren; O Stål; B Nordenskjöld
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.